Sapreme develops macromolecule therapeutics by circumventing endosomal entrapment.
Its endosomal escape platform enables access to intracellular targets with minimal toxicity. The approach is used in Sapreme’s internal pipeline.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The platform is available for partnering without limitation to biologic modality or indication.
The platform permeabilizes endo-lysosomal membranes to release trapped macromolecules and increase target engagement without negatively impacting plasma membrane integrity.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Open the published source list.RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 2, 2026, September 14, 2026, September 15, 2026 and September 19, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.